Viridian Therapeutics, Inc.\DE (VRDN) Interest & Investment Income (2018 - 2026)

Viridian Therapeutics, Inc.\DE's Interest & Investment Income history runs 9 years deep, the most recent figure standing at $7.9 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 2987.06% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $40.2 million (up 149.74% YoY), while the FY2025 annual figure was $27.4 million, down 13.29% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $7.9 million, down from $27.0 million in the prior quarter.
• The five-year high for Interest & Investment Income was $27.0 million in Q4 2025, with the low at -$12.3 million in Q4 2023.
• The 5-year median for Interest & Investment Income is $3.4 million (2022), against an average of $3.6 million.
• The sharpest annual moves came in 2023 and 2026: Interest & Investment Income slumped 456.65% in 2023, then surged 2987.06% in 2026.
• Viridian Therapeutics, Inc.\DE's Interest & Investment Income stood at $3.4 million in 2022, then plunged by 456.65% to -$12.3 million in 2023, then jumped by 169.26% to $8.5 million in 2024, then soared by 217.21% to $27.0 million in 2025, then slumped by 70.87% to $7.9 million in 2026.
• Business Quant data shows VRDN's Interest & Investment Income at $7.9 million in Q1 2026, $27.0 million in Q4 2025, and $5.5 million in Q3 2025.